TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Tessera Therapeutics
Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

Tessera Therapeutics presented promising preclinical data at the ASH Annual Meeting, demonstrating significant progress in Gene Writing technology for sickle cell disease and T cell therapies, with successful in vivo editing of long-term hematopoietic stem cells and generation of functional CAR-T cells in non-human primates.

Insights
JPMpD   neutral

Mentioned as a previous employer of Zastre & Co's founding team, with no direct positive or negative implications


REGN   neutral

Mentioned in a separate collaboration context with minimal details in this article